folio in the second quarter of 2011, Idenix is in the business of developing and commercializing medicines that treat human viral and infectious diseases, such as hepatitis C and hepatitis B and HIV/AIDS. Idenix is headquartered in Cambridge, Mass., with a market cap of $544.5 million.For the past consecutive five quarters since acquiring Idenix, Klarman has outstandingly increased his shares of t